Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.

AstraZeneca has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for ...

The Business Research Company's Imfinzi (durvalumab) Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to ...

Overall survival at two years was 82.2 per cent in the durvalumab group and 75.2 per cent in the comparator group. Durvalumab ...

AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) for use of its lung cancer drugs Tagrisso (osimertinib) and Imfinzi ...

NBTX stock rises following initiation of dosing in a mid-stage NSCLC study evaluating a potential first-in-class ...

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...

Durvalumab (Imfinzi, AstraZeneca) with platinum-based chemotherapy as neoadjuvant treatment, and then as monotherapy after surgery, is indicated for 'the treatment of adults with resectable (tumours ≥ ...

A “game-changer” study claims bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive. Patients with advanced ...

A lung cancer drug already available on the NHS has been proven to cut bladder cancer deaths and reduce the risk of the ...

Bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to ...